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pondence of each voxel with respect to the planning CT. The widely 
applied intensity-based algorithms operate globally on the whole 
image. They are not capable of accurately matching large heteroge-
neous deformations as occur in the bladder area.  
A number of feature-based approaches are used like the Finite Ele-
ment Method (FEM). The FEM describes the forces in the bladder and 
deforms the organs according to urine filling by solving the stress 
equations. Such models are in principle able to yield a good anatomi-
cal correspondence. However, for their best performance they require 
detailed knowledge of the tissue properties which is not yet available. 
A more heuristic approach can be followed by application of the 
Symmetric Thin Plate Spline Robust Point Matching algorithm. Points 
are placed on the surfaces of the volumes that have to be matched. 
Subsequently, the distances of these points are minimized. Recently, 
the algorithm is modified with a weight parameter to allow flexibility 
control of the tumor and bladder wall. They are considered as sepa-
rate structures, with a more flexible bladder. Rather coherent regis-
trations are achieved, with lower marker errors for the modified 
algorithm (Figure). 
It can be concluded that important progress has been made to effec-
tively improve bladder cancer irradiation. An important role is played 
by the cystoscopic guided tumor demarcation to visualize the tumor 
during treatment. Sparing of normal tissue is achieved by the adaptive 
procedures. Improvements have to be achieved for better practical 
support of clinical ART procedures and deformable image registration 
for accurate dose accumulation. 
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By using the unique resources for conducting epidemiological research 
that we have in the Nordic countries, facilitated by the existence of 
nationwide population and health registries that can be accessed with 
unique individual identification numbers, several population-based, 
studies have been conducted within the Nordic countries to evaluate 
the impact of cancer therapy at a young age on the health of the 
patients and their offspring.  
Three different population-based, nationwide studies will be pre-
sented as examples of clinical epidemiological studies on late effects 
of childhood cancer with outcome data derived from health registries 
and a ‘gold standard’ approach being used for exposure assessment 
including organ radiation dosimetry: (1) A case–cohort study based on 
the population-based cohort of Danish childhood cancer patients and 
all their children with the purpose to quantify the extent to which 
cancer therapy contributes to genetic disease in the children of 
survivors including chromosomal abnormalities, congenital malforma-
tions, stillbirths, and neonatal deaths as possible indicators of genetic 
damage in the next generation. Preconception radiation doses to the 
gonads, uterus, and pituitary gland and administered chemotherapy 
have been quantified from medical records and related to adverse 
outcomes using a generalized estimating equation model and the 
results will be presented. (2) A greater international collaboration to 
study trans-generational effects of cancer treatment in children and 
adolescents – the Genetic Consequences of Cancer Treatment (GCCT) 
study - currently under way in Denmark, Finland and the USA with a 
similar design but with an increased sample size by adding the 
offspring of cancer survivors diagnosed in early adulthood in both 
Denmark and Finland (www.gcct.org). This study is expected to 
provide more definitive answers to questions about the integrity of 
the germline in human populations that have been exposed to muta-
genic cancer therapy. (3) A large ongoing Adult Life after Childhood 
Cancer in Scandinavia (ALiCCS; www.aliccs.org) study of late effects 
in childhood cancer patients. The Nordic cohort consists of nearly 
33,000 children and adolescents with cancer diagnosed below age 20 
in Denmark, Finland, Iceland, Norway, and Sweden. Morbidity-specific 
incidence and cause-specific mortality in these patients will be com-
pared with that of a combined Nordic cohort of more than 212,000 
population-based comparisons. In a cohort surveillance approach, the 
relative and absolute risks for different chronic diseases in adult 
survivors will be assessed based on discharge diagnoses in national 
patient registries. In the initial phase of this research initiative, 
priority is given to late effects in terms of cardiovascular and pulmo-
nary disorders, endocrine disorders and reproductive failures, 
and renal and gastrointestinal disorders. Based on the findings in this 
screening phase, specific, well-defined outcomes will be investigated 
in case-cohort studies among 5-year survivors in order to investigate 
associations, including dose-response, between specific treatment 
regimens and selected outcomes. Detailed information on chemothe-
rapy including drugs and doses and radiotherapy will be abstracted 
from medical records and for some of the studies organ radiation 
doses from direct and scattered irradiation will be estimated.  
The strengths of these studies include the unbiased ascertainment of 
cancer cases through a search in nationwide cancer registries, com-
plete identification of their children (for offspring studies) and un-
biased identification of population comparisons, and long-term, 
virtually complete follow-up of all study populations. 
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Adverse effects of cancer treatment (normal tissue damage, new 
malignancies) represent well-studied phenomena across the radiation 
disciplines. Novel steps are needed to fully exploit current technical 
opportunities to avoid normal tissue radiation exposure. Pediatric 
oncology represents a good model to illustrate the proposed ap-
proaches. On average pediatric cancer patients have a better progno-
sis than adults, they are exposed to radiotherapy and chemotherapy in 
vulnerable periods of growth and development, treatment field 
delineation can be challenging due to close proximity of surrounding 
organs in small children, and these patients are at potential risk for a 
variety of health problems at different points in their life span.  Valid 
dose effect studies require accurate characterization of radiation dose 
characteristics combined with complete and accurate follow-up for 
health effects, including uniform definitions for such health outcomes. 
 In the past, collaborative groups of pediatric oncologists, epidemiolo-
gists, and radiation oncologists have initiated large observational 
follow-up studies of cancer survivors, to quantify dose effect relation-
ships for chemotherapy and radiotherapy. The professionals who treat 
childhood cancer patients typically follow trial protocols, thus allow-
ing for large, often international, trial based late effects follow up 
studies. These studies seemingly represent rather separate, parallel 
efforts, often using different terminology but seeking answers to 
closely related or identical questions. From a methodologic perspec-
tive, trial based follow-up efforts are based on excellent dose assess-
ment methods but face challenges in achieving uniform and complete 
health outcome follow-up beyond 10 or even 5 yrs post treatment. 
Conversely, observational retrospective follow-up studies typically 
have reasonable or good health outcome data, currently on average 
spanning 30+ yrs of follow-up for the oldest pediatric cancer survivors, 
however, it has remained challenging to accurately describe doses at 
organs at risk according to the standards common (and expected) in 
clinical radiation oncology.  In essence, we need to combine the dose 
estimation standard from clinical trials with the follow-up methods 
applied in observational studies. Several parallel approaches should 
